SRP-9001  
Protocol  SRP-9001 -102 (Version 9, Amendment 8 ) 
1 
CONFIDENTIAL   
CLINICAL STUDY PROTO COL  
DRUG:  SRP-9001 (formerly referred to as 
rAAVrh74.MHCK7.micro dystrophin )  
STUDY NUMBER:  SRP-9001 -102  
STUDY TITLE:  A Mu lticenter, Randomized, Double -Blind, Placebo -
Controlled Trial for Duchenne Muscular Dystrophy 
Using SRP -9001  
IND NUMBER:  [ZIP_CODE]  
SPONSOR:  Sarepta Therapeutics, Inc.  
[ADDRESS_1076842]  
Cambridge, MA [ZIP_CODE] [LOCATION_003]  
Phone: +1 -[PHONE_16338]  
CURRENT VERSION DATE:  Version 9 (Amendment 8), 12 April  2023  
REPLACES VERSION DATE:  Version 8 (Amendment 7), [ADDRESS_1076843] 2020  
Version 7 (Amendment 6), 18 May 2020  
Version 6 (Amendment 5), 25 September 2019  
Version 5 (Amendment 4), 02 July 2019  
Version 4 (Amendment 3), 04 June 2019  
Version 3 (Amendment 2), 26 February  2019  
Version 2 (Amendment 1), 09 November  2018  
Version 1 (Amendment 0), [ADDRESS_1076844]/Independent Ethics Committee and Review 
by a Regulatory Authority as required by [CONTACT_4913], without the written authorization of 
the Sponsor, except to the extent necessary to obtain written informed consent from those individuals to whom 
the drug may be administered. These restrictions will continue to apply after the study  has closed.  

SRP-9001  
Protocol  SRP-9001 -102 (Version 9, Amendment 8 ) 
3 
CONFIDENTIAL  INVESTIGATOR’S AGREEMENT  
 
I have received and read the Investigator’s Brochure for SRP -9001. I have read the 
SRP-9001 -102 Study Protocol (Version 9, Amendment 8 dated 12 April 2023 ) and agree to 
conduct the study as outlined. I agree to maintain the confidentiality of al l information received 
or developed about this protocol.  
 
 
 
 
Printed Name [CONTACT_783199]-9001  
Protocol  SRP-9001 -102 (Version 9, Amendment 8 ) 
4 
CONFIDENTIAL  TABLE OF CONTENTS  
CLINICAL STUDY PROTO COL  ................................ ................................ ................................ ..1 
SIGNATURE [CONTACT_1783]  ................................ ................................ ................................ ....................... 2 
INVESTIGATOR’S  AGREEMENT  ................................ ................................ ............................... [ADDRESS_1076845] OF ABBREVIATIONS AND DE FINITIONS OF TERMS  ................................ .................. 9 
1. PROTOCOL SUMMARY  ................................ ................................ .......................... 11 
1.1. Synopsis  ................................ ................................ ................................ ...................... 11 
1.2. Schema  ................................ ................................ ................................ ........................ 15 
1.3. Schedule of  Activities  ................................ ................................ ................................ .16 
2. INTRODUCTION  ................................ ................................ ................................ ......21 
2.1. Study Rationale  ................................ ................................ ................................ ........... 21 
2.2. Background  ................................ ................................ ................................ ................. 21 
2.3. Benefit/Risk Assessment  ................................ ................................ ............................ 22 
3. STUDY DESIGN  ................................ ................................ ................................ .......23 
3.1. Overall Design  ................................ ................................ ................................ ............ 23 
3.1.1.  Screening/Baseline Period  ................................ ................................ .......................... 23 
3.1.2.  Treatment Period  ................................ ................................ ................................ ........ 23 
[IP_ADDRESS].  Part 1  ................................ ................................ ................................ ........................... 23 
[IP_ADDRESS].  Part 2  ................................ ................................ ................................ ........................... 24 
[IP_ADDRESS].  Part 3  ................................ ................................ ................................ ........................... 25 
3.2. Scientific Rationale for Study Design  ................................ ................................ ........ 26 
3.3.  ................................ ................................ ................................ ..26 
3.4. End of Study Definition  ................................ ................................ .............................. 27 
4. STUDY POPULATION  ................................ ................................ ............................. 28 
4.1. Inclusion Criteria  ................................ ................................ ................................ ........ 28 
4.2. Exclusion Criteria  ................................ ................................ ................................ .......28 
4.3. Lifestyle Considerations  ................................ ................................ ............................. 29 
4.4. Screen Failures  ................................ ................................ ................................ ............ 29 
5. STUDY  INTERVENTION  ................................ ................................ ........................ 30 
5.1. Study Intervention(s) Administered  ................................ ................................ ........... 30 
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9, Amendment 8 ) 
[ADDRESS_1076846]-infusion Immunosuppressants  ................................ ................................ ............ 30 
5.1.3.  Intravenous Infusion (Day 1, Part 1 and Part 2)  ................................ ......................... [ADDRESS_1076847] Infusion Monitoring  ................................ ................................ ............................ 31 
[IP_ADDRESS].  Immediately Following Infusion  ................................ ................................ ................ 31 
[IP_ADDRESS].  Extended Follow -up ................................ ................................ ................................ ....31 
5.2. Preparation/Handling/Storage/Accountability  ................................ ............................ 31 
5.3. Measures to Minimize Bias: Randomization and Blinding  ................................ ........ 31 
5.3.1.  Establish Patient Identification Number  ................................ ................................ .....31 
5.3.2.  Assignment to a Treatment Group  ................................ ................................ .............. 31 
5.3.3.  Randomization  ................................ ................................ ................................ ............ 32 
5.3.4.  Blinding/Unblinding  ................................ ................................ ................................ ...32 
5.4. Concomitant Therapy  ................................ ................................ ................................ .33 
5.4.1.  Rescue Medicine  ................................ ................................ ................................ ......... 33 
5.5. Dose Modification  ................................ ................................ ................................ ......33 
5.5.1.  Stoppi[INVESTIGATOR_1869]  ................................ ................................ ................................ ............ 33 
5.5.2.  Dosing Schedule  ................................ ................................ ................................ ......... 33 
5.6. Study Discontinuation  ................................ ................................ ................................ 34 
5.7. Intervention after the End of the Study  ................................ ................................ .......34 
6. STUDY ASSESSMENTS AN D PROCEDURES  ................................ ...................... 35 
6.1. Efficacy Assessments  ................................ ................................ ................................ .35 
6.1.1. Muscle Biopsy  ................................ ................................ ................................ ............ 35 
6.1.2.  Immunofluorescence Fiber Intensity / Immunofluorescence PDPF  ........................... 35 
6.1.3.   ................................ ................................ ................... 35 
6.1.4.  t ................................ ................................ ....................... 35 
6.1.5.  Physical Functional Assessments  ................................ ................................ ............... 36 
[IP_ADDRESS].  Time to Rise from the Floor  ................................ ................................ ....................... 36 
[IP_ADDRESS].  Ascend 4 Steps  ................................ ................................ ................................ ............ 36 
[IP_ADDRESS].  North Star Ambulatory Assessment  ................................ ................................ ........... 36 
[IP_ADDRESS].  10-meter Timed Test  ................................ ................................ ................................ ...36 
[IP_ADDRESS].  100-meter Timed Test  ................................ ................................ ................................ .36 
6.2. Safety Assessments  ................................ ................................ ................................ .....36 
6.2.1. Physical Examinations  ................................ ................................ ................................ 36 
CCI
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9, Amendment 8 ) 
6 
CONFIDENTIAL  6.2.2.  Vital Signs  ................................ ................................ ................................ .................. 37 
6.2.3.  Electrocardiograms and Echocardiograms  ................................ ................................ .37 
6.2.4.  Clinical Safety Laboratory Assessments  ................................ ................................ ....37 
6.2.5.  Safety Monitoring  ................................ ................................ ................................ .......39 
[IP_ADDRESS].  Safety Monitoring for Liver Chemistry Tests  ................................ ............................ 39 
[IP_ADDRESS].  Safety Monitoring for Hypersensitivity and Complement -Mediated 
Reactions  ................................ ................................ ................................ ..................... 39 
[IP_ADDRESS].  Safety Monitoring for Platelet Count Results  ................................ ............................. 40 
[IP_ADDRESS].  Safety Monitoring for Rhabdomyolysis  ................................ ................................ .....41 
6.2.6.   ................................ ................................ ...................... 41 
6.2.7.   ................................ ................................ ................................ ......... 42 
6.2.8.   ................................ ................................ ................ 42 
6.3. Adverse Events and Serious Adverse Events  ................................ ............................. 42 
6.3.1.  Collection of Adverse Events  ................................ ................................ ..................... 42 
6.3.2.  Definition of Adverse Events  ................................ ................................ ..................... 42 
[IP_ADDRESS].  Adverse Event  ................................ ................................ ................................ ............. 42 
[IP_ADDRESS].  Serious Adverse Events  ................................ ................................ .............................. 43 
[IP_ADDRESS].  Adverse Events of Special Interest  ................................ ................................ ............. 43 
6.3.3.  Classification of Adverse Events  ................................ ................................ ................ 43 
[IP_ADDRESS].  Relationship to Investigational Product  ................................ ................................ ......43 
[IP_ADDRESS].  Relationship to Study Procedures  ................................ ................................ ............... 44 
[IP_ADDRESS].  Relationship to Underlying Disease  ................................ ................................ ........... 44 
[IP_ADDRESS].  Severity of Adverse Events  ................................ ................................ ........................ 44 
[IP_ADDRESS].  Outcome  ................................ ................................ ................................ ...................... 44 
[IP_ADDRESS].  Action Taken Regarding the Investigational Product  ................................ ................. 45 
[IP_ADDRESS].  Expectedness of an Adverse Event  ................................ ................................ ............. 45 
[IP_ADDRESS].  Suspected Unexpected Serious Adverse Reactions  ................................ .................... 45 
6.3.4.  Recording of Adverse Events  ................................ ................................ ..................... 45 
6.3.5.  Reporting Serious Adverse Events  ................................ ................................ ............. 45 
6.3.6.  Special Situations  ................................ ................................ ................................ ........ 46 
[IP_ADDRESS].  Overdose  ................................ ................................ ................................ ..................... 46 
[IP_ADDRESS].  Adverse Events of Special Interest  ................................ ................................ ............. 46 
[IP_ADDRESS].  Death  ................................ ................................ ................................ ........................... 46 
CCI
CCI
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9, Amendment 8 ) 
7 
CONFIDENTIAL  [IP_ADDRESS].  Unblinding due to a Medical Emergency  ................................ ................................ ...47 
6.3.7.  Responsibilities of the Investigator  ................................ ................................ ............ 47 
6.3.8.  Responsibilities of the Sponsor  ................................ ................................ .................. 47 
6.4. Treatment Overdose  ................................ ................................ ................................ ....48 
6.5. Pharmacokinetics  ................................ ................................ ................................ ........ 48 
6.6. Pharmacodynamics  ................................ ................................ ................................ .....48 
6.7.  ................................ ................................ ................................ ..48 
6.7.1.   ................................ ................................ .................... 49 
6.7.2.   ................................ ................................ ............................ 49 
6.8. Biomarkers  ................................ ................................ ................................ .................. 49 
6.9.  ................................ .................... 49 
6.9.1.   ................................ ................................ ................................ .....49 
6.9.2.   ................................ .................. 50 
7. STATISTICAL CONSIDER ATIONS  ................................ ................................ .......51 
7.1. Statistical Hypotheses  ................................ ................................ ................................ .51 
7.2. Sample Size Determination  ................................ ................................ ........................ 51 
7.3. Analysis Populations  ................................ ................................ ................................ ..52 
7.4. Statistical Analyses  ................................ ................................ ................................ .....52 
7.4.1.  Efficacy Analyses  ................................ ................................ ................................ .......52 
7.4.2. Safety Analyses  ................................ ................................ ................................ .......... 53 
7.5. Interim Analyses  ................................ ................................ ................................ ......... 54 
7.5.1.  Interim Analysis at Week 12 in Part 1  ................................ ................................ ........ 54 
7.5.2.  Interim Analysis at the Completion of Part 1  ................................ ............................. 54 
7.5.3.   ................................ .......... 54 
7.5.4.  Interim Analysis Based on Regulat ory Interactions  ................................ ................... 54 
7.6. Data Monitoring Committee  ................................ ................................ ....................... 54 
8. DISCONTINUATION OF S TUDY INTERVENTION AN D 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL  ................................ .......55 
8.1. Discontinuation of Study Intervention ................................ ................................ ........ 55 
8.2. Participant Discontinuation/Withdrawal from the Study  ................................ ........... [ADDRESS_1076848] to Follow -up ................................ ................................ ................................ .......55 
9. SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  ................................ ................................ ................................ ..57 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9, Amendment 8 ) 
8 
CONFIDENTIAL  9.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations  .................... 57 
9.1.1.  Clinical Monitoring of the Study  ................................ ................................ ................ 57 
9.1.2.  Regulatory and Ethical Consideratio ns ................................ ................................ ......57 
9.1.3.  Financial Disclosure  ................................ ................................ ................................ ...58 
9.1.4.  Informed Consent Process  ................................ ................................ .......................... 58 
9.1.5.  Data Protection  ................................ ................................ ................................ ........... 59 
[IP_ADDRESS].  Data Safety Monitoring Plan  ................................ ................................ ...................... 59 
9.2. Committees Structure  ................................ ................................ ................................ .59 
9.2.1. Data Monitoring Committee  ................................ ................................ ....................... 59 
9.2.2.  Dissemination of Clinical Study Data  ................................ ................................ ........ 59 
[IP_ADDRESS].  Final Study Report  ................................ ................................ ................................ ......59 
9.2.3.  Source Documents  ................................ ................................ ................................ ......59 
9.2.4. Publication Policy  ................................ ................................ ................................ .......59 
9.3. Appendix 2:  ................................ ................................ ................................ .[ADDRESS_1076849] OF TABLES  
Table  1: Schedule of Activities – Part 1  ................................ ................................ ................... 16 
Table  2: Schedule of Activities – Part 2  ................................ ................................ ................... 18 
Table  3: Schedule of Activities – Part 3 Open -Label Follow -Up ................................ ............. 20 
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9, Amendment 8 ) 
[ADDRESS_1076850] research organization  
DMC  data monitoring committee  
DMD  Duchenne muscular dystrophy  
  
ECG  electrocardiogram  
ECHO  echocardiogram  
GCP  Good Clinical Practices  
GGT  gamma -glutamyl transferase  
GLDH  glutamate dehydrogenase  
HIV human immunodeficiency virus  
ICF informed consent form  
ICH International Council on Harmonisation  
IEC Independent Ethics Committee  
CCI
CCI
CCI
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9, Amendment 8 ) 
[ADDRESS_1076851]  
ITT intent -to-treat 
IV intravenous(ly)  
IXRS  interactive voice/web response system  
  
NOAEL  no observable adverse effect level  
NSAA  North Star Ambulatory Assessment  
PCS potentially clinically significant  
PDPF  percent dystrophin positive fibers  
PI [INVESTIGATOR_783144] -emergent adverse event  
ULN  upper limit of normal  
WBC  white blood cell  
CCI
CCI
CCI
CCI
CCI
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9, Amendment 8 ) 
11 
CONFIDENTIAL  1. PROTOCOL SUMMARY  
1.1. Synopsis  
Protocol Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial for 
Duchenne Muscular Dystrophy Using SRP -9001  
Short Title:  A Randomized, Double -Blind, Placebo -Controlled Study of SRP-9001  for 
Duchenne Muscular Dystrophy  
Rationale : Based on nonclinical studies in mice and canine species deficie nt in dystrophin and 
from the 2006 Duchenne muscular dystrophy (DMD) trial ( Mendell 2010 ) and the ongoing 
microDys -IV-001 clinical trial, data supports the use of gene transfer for micro -dystrophin 
expression in skeletal and cardiac muscle.   
Objectives and Endpoint s: This study will assess the safety and efficacy of exogenous gene 
transfer in DMD patients by [CONTACT_783162] 3 parts: two 48-week 
randomized, double -blinded, placebo -controlled p eriod s (Part 1  and 2 ), and an open -label 
follow -up period  (Part 3) . The primary objectives of this study are the assessments of the safety 
and efficacy of intravenous (IV) administration of SRP -9001 in DMD patients . 
Objectives  Endpoints  
Safety  
• To evaluate the safety of SRP-9001   • Treatment -emergent adverse events ( TEAE s) 
and serious adverse events ( SAE s) 
• Select c linical laboratory assessments  
Primary  
• To evaluate micro -dystrophin expression from  
SRP-[ADDRESS_1076852] dosing  (Part  1) as 
measured by [CONTACT_783163]  • Change in  quantity of micro -dystrophin protein 
expression from Baseline to Week 12  (Part 1) 
as measured by [CONTACT_27187]  
• To evaluate the effect of SRP -9001 on physical 
functional assessments as assessed by [CONTACT_783164]  (NSAA)  over 
48 weeks (Part 1)  • Change in NSAA total score from Baseline to 
Week 48  (Part 1)  
SRP-9001  
Protocol  SRP-9001 -102 (Version 9, Amendment 8 ) 
12 
CONFIDENTIAL  Objectives  Endpoints  
Secondary  
• To evaluate the effect of SRP -9001 on physical 
functional assessments over 48 weeks (Part 1)  • Change in time to rise from the floor from 
Baseline to Week 48  (Part 1)  
• Change in time to ascend 4 steps from 
Baseline  to Week 48  (Part 1)  
• Change in time of [ADDRESS_1076853] from 
Baseline to Week 48  (Part 1)  
• Change in time of [ADDRESS_1076854] from 
Baseline to Week 48  (Part 1)  
• To evaluate micro -dystrophin  expression from 
SRP-9001 at 12 weeks  (Part  1) as measured by 
[CONTACT_31122] (IF) fiber intensity  of 
biopsied muscle tissue  • Change in micro -dystrophin expression from 
Baseline to Week 12 (Part 1) as measured by 
[CONTACT_783165]   
• To evaluate micro -dystrophin expression from 
SRP-9001 at 12 weeks (Part  1) as measured by 
[CONTACT_783166] (PDPF)  of 
biopsied muscle tissue  • Change in micro -dystrophin expression from 
Baseline to Week 12 (Part 1) as measured by  
[CONTACT_783167]-9001  
Protocol  SRP-9001 -102 (Version 9, Amendment 8 ) 
13 
CONFIDENTIAL  
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9, Amendment 8 ) 
14 
CONFIDENTIAL   
 
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
16 
CONFIDENTIAL  
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
17 
CONFIDENTIAL   
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
18 
CONFIDENTIAL  
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
19 
CONFIDENTIAL   
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
20 
CONFIDENTIAL  
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
21 
CONFIDENTIAL  2. INTRODUCTION  
SRP-9001 is a nonreplicating, recombinant adeno -associated virus (AAV)  that is being 
developed for treatment in patients with Duchenne muscular dystrophy (DMD).  
2.1. Study Rationale  
There is a strong rationale for systemic gene delivery in young DMD boys based on studies 
of the natural history of this disease. Gene replacement therapy has been studied for the past 
[ADDRESS_1076855] benefit to patients. Utilizing the 
rAAVrh74 serotype allows for efficient transduction of cardiac, skeletal, and di aphragm muscle 
without the increased risk of regional delivery strategies. Increased dystrophin expression in vivo 
may potentially improve patient ’s muscle function. SRP-[ADDRESS_1076856] common, severe childhood form of muscular 
dystrophy . Inheritance follows an X -linked recessive pattern . Birth prevalence has been 
estimated at 1 in 3500 to 5000 live male births (Mendell 2010 ). Approximately one-third of cases 
represent new mutations of the DMD  gene with the remaining inherited on the X chromosome 
from a carrier mother . Questions usually begin to surface between 3 to 5 years of age regarding 
reduced motor skills that alert a need for diagnosti c evaluation . Earlier recognition results from 
delay in motor milestones or family history. At times aminotransaminases  are found to be 
elevated that lead to detection of creatine kinase (CK)  elevation and subsequent further testing. 
Duchenne muscular dyst rophy is relentlessly progressive with loss of ambulation by 12  years of 
age (Brooke 1983 ). Historically, patients died from respi[INVESTIGATOR_11800] . Now, a variety of 
factors protect the respi[INVESTIGATOR_783145], antibiotics, 
vaccines, and other ancillary methods  (Eagle 2002 ). Consequently, patients tend to live longer 
but eventually succumb to cardiac failure ( D’Amario 2017 ). 
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
22 
CONFIDENTIAL  2.3. Benefit/Risk Assessment  
Nonclinical data and results from clinical study SRP -[ADDRESS_1076857] a positive benefit/risk 
relationship and support clinical investigation of SRP -9001 gene replacement in DMD patients.  
More detailed information about the known an d expected benefits and risks and reasonably 
expected adverse events (AEs) of SRP -9001 may be found in the Investigator’s Brochure.  
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
23 
CONFIDENTIAL  3. STUDY DESIGN  
3.1. Overall  Design  
This is a randomized, double -blind, placebo -controlled, 3-part clinical study  of systemic gene 
delivery of SRP -9001 in up to 44 DMD patients 4 to 7 years of age (inclusive) who either have 
a confirmed frameshift deletion or duplication between exons  18 to 58, or premature stop codon 
mutation  between exons 18 to 58 . Patients meeting  all eligibility criteria will be randomized to 
SRP-9001 or placebo by [CONTACT_6946]/web response system (IXRS). All patients will 
have the opportunity to receive intravenous ( IV) SRP-9001 ( 1.33 × 1014 vg/kg ) in either Part 1 or 
Part 2.  Part 3 of t he study will be an open -label follow -up period.  
The Sponsor has developed a quantitative polymerase chain reaction ( qPCR ) method using  
a linear standard for dose titering. This method replaces the previously used qPCR method 
which  used a supercoiled stan dard for dose titering developed by [CONTACT_347475]’s 
Hospi[INVESTIGATOR_307]. The scale for the linear standard method is different from the previous supercoiled 
standard method. For patients who received a dose  in this study  based on Nationwide Children’s 
Hospi[INVESTIGATOR_783146] , the dose used was 2  × 1014 vg/kg  which corresponds to  
1.33 × 1014 vg/kg  as measured by [CONTACT_1034]’s  qPCR method using a  linear standard. Note that 
both numbers (ie, 2  × 1014 and 1.33  × 1014 vg/kg ) refe r to the same quantity of drug given to the 
patient s; only the effective scale for the 2  methods is different. Hence, as of Amendment 5, 
Version 6, the reassigned dose for the additional patients in the study is 1.33  × 1014 vg/kg , and 
for the duration of t his study, all references to dosing will use 1.33  × 1014 vg/kg . 
3.1.1.  Screening/Baseline  Period  
The Screening/Baseline period will be up to 4 weeks before  Day -1 in Part 1 . After obtaining 
informed consent, patients will be evaluated for eligibility . Screening will include collection 
of demographics and medical history, vital sign measurements, a physical examination, 
electrocardiogram (ECG), and an echocardiogram (ECHO) . Blood and urine samples will be 
collected for clinical and safety labo ratory assessments. B lood samples will also be collected 
for hepatitis B and C, human immunodeficiency virus (HIV),  and antibodies to rAAV rh74 and 
antigen -specific T -cells to rAAVrh74 capsid and micro -dystrophin . A pretreatment muscle 
biopsy will involve the gastrocnemius musc le, or a muscle selected by [CONTACT_079]  
(PI) and will be performed  after eligibility but before Day -1 in Part 1 . The parent/caregiver will 
be asked to complete questionnaires.  
Physical functional assessments will include the time to rise from the floor, time to ascend 
4 steps, North Star Ambulatory Assessment ( NSAA ), the 10-meter timed test, and the 100-meter 
timed test . 
3.1.2.  Treatment Period  
[IP_ADDRESS].  Part 1  
Part 1 is a 48 -week randomized, double -blind, placebo -controlled period. Patients meeting 
eligib ility requirements will be randomized prior to or on Day -1 to SRP -9001 or placebo in a 
1:1 ratio by [CONTACT_18375]. Up to 22 patients will receive IV SRP -9001 ( 1.33 × 1014 vg/kg ) and up to  
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
24 
CONFIDENTIAL  22 patients will receive  a matching volume ( up to  10 mL/kg ) of placebo (lact ated Ringer’s 
solution).  
Patients may be admitted to the hospi[INVESTIGATOR_783147] . On Day -1, the patient will receive a physical examination, have 
vital signs collected, and provide blood  and urine samples.   
The day prior to the study treatment infusion  (SRP -9001 or placebo) , patient ’s background dose 
of steroid for DMD  will be increased to  at least 1 mg/kg of a glucocorticoid  (prednisone 
equivalent) daily  and continue at this level  for at  least [ADDRESS_1076858] of the patient.  
SRP-9001 or placebo will be administered IV on Day 1 over 1 to 2 hours. Vital signs will be 
monitored during and after the infusion acc ording to the Study Operations Manual.  
On the day after the infusion (Day 2), patients will receive a physical exam ination , have vital 
signs collected, and provide blood and urine samples before being discharged  or in clinic, as 
applicable .  
Patients will  be followed for 48 weeks  in Part 1 . Patients will complete clinic follow -up visits at 
the following time points: relative to the infusion on 
Day 1). In addition, at , patients will complete follow -up visits for assessment of  
liver function tests . If the  visits occur in the clinic,  a blood sample for the 
assessment of glutamate dehydrogenase (GLDH ) will be collected.  
All patients will have a muscle biopsy performed  at Week 12 in Part 1 .  
 
 
  
All patients, parents, caregivers, the Examining Team, the Treating Team, physiotherapi[INVESTIGATOR_11437], and 
clinical staff will be blinded to the treatment the patient receives (SRP -9001 or placebo). The 
study will be unblinded when the last patient completes the  visit. Refer to the 
study unblinding plan for additional details.  
Safety will be assessed by [CONTACT_783168] -emergent adverse events (TEAE s), serious 
adverse events ( SAE s), and select laboratory assessments.  
Refer to Section  6 Study Assessments and Procedures for additional information.   
[IP_ADDRESS].  Part 2  
Part 2 of the study will begin after the patient completes Part 1. Patients who were randomized 
to placebo during Part 1 will receive IV SRP -9001 ( 1.33 × 1014 vg/kg ) in Part 2. To maintain 
blinding throughout the study, patients previously randomized and treated with SRP -9001 in 
Part 1 will receive up to 10 mL/kg placebo (lactated  Ringer’s  solution ). Infusions will be given 
in the same manner as in Part 1.  
 
 
 
 
CCI
CCI
CCI
CCI
CCI
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
25 
CONFIDENTIAL   
 
•  
•  
•  
 
 
 
 
Prior to dosing in Part 2, if a patie nt has rAAVrh74 antibody titers > 1:400, consultation with the 
unblinded contract research organization (CRO)  Medical Director , blinded Sponsor Medical 
Director, and PI [INVESTIGATOR_783148]. Patients who received placebo in Part [ADDRESS_1076859] rAAVrh74 antibody titers > 1:[ADDRESS_1076860] planned visit based on the protocol as their final visit.  
The day prior to the study treatment  (SRP -9001 or placebo)  infusion  in Part 2 , the patient ’s dose 
of steroids will be increased to at least 1 mg/kg of a glucocorticoid (prednisone equivalent) daily 
and continue at this level for at least [ADDRESS_1076861] laboratory assessments.  
Refer to Section  6 Study Assessments and Procedures for additional information.  
[IP_ADDRESS].  Part [ADDRESS_1076862] patient completes the  visit ; refer to the study unblindi ng plan for additional 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
[ADDRESS_1076863] complete the Week 130 visit at a minimum before rolling over into the long -term 
extension study. After completion of the Week 130 visit, if patients  decide not to continue their 
follow -up in the long -term extension study, patients  will complete an end of study visit.  
3.2. Scientific  Rationale for Study Design  
Based on the hypothesis that micro -dystrophin expression can improve sarcolemmal integrity 
resulting in improved  cardiac  and skeletal  muscle function as well as preliminary results from the 
ongoing study (Study  SRP-9001 -101), this study will further assess the safety and efficacy of 
exogenous gene transfer in DMD patients measuring biologic and clinical efficacy endpoints.  
3.3.  
CCI
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
[ADDRESS_1076864] complete the Week 130 visit at a minimum before rolling over into the long -term 
extension study. After completion of the Week 130 visit, if subjects decide not to continue their 
follow -up in the long -term extension study, subjects will complete  an end of study visit.  
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
28 
CONFIDENTIAL  4. STUDY POPULATION  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, are not permitted.  
4.1. Inclusion Criteria  
Participants are eligible to be included in the  study only if all of the following criteria apply:  
1. Male, 4 to 7 years of age, inclusive , at the time of screening in Part 1 . 
2. Molecular characterization of the DMD gene with either frameshift (deletion or 
duplication)  between exons 18 to 58 , or premature s top codon mutation between 
exons  18 to 58 . 
3. Indication of symptomatic muscular dystrophy:  
  
 
4. Ability to cooperate with motor assessment testing . 
5. Stable dose equivalent of oral corticosteroids for at least 12 weeks before  screening and 
the dose is expected to remain constant (except for potential modifications to 
accommodate changes in weight) throughout Part 1 and 2 of the study . 
4.2. Exclusion Criteria   
Participants are excluded from the study if any of the following criteria apply:  
1. Signs of cardiomyopathy, including ECHO   
2. Serological evidence of HIV infection, or Hepatitis B or C infection.  
3. Diagnosis of (or ongoing treatmen t for) an autoimmune disease.  
4. Concomitant illness or requirement for chronic drug treatment that in the opi[INVESTIGATOR_783149].  
5. Has a medical condition or extenuating circumstance that, in the opi[INVESTIGATOR_783150], might compromise the patient ’s ability to comply with the protocol required 
testing or procedures or compromise the patient ’s wellbeing, safety, or clinical 
interpretability.  
6. Severe infection (eg, pneumonia, pyelonephritis, or meningitis) within  before 
study treatment infusion . 
7. Demonstrates cognitive impairment that could confound motor development in the 
opi[INVESTIGATOR_689].  
8. Has received any investigational medication (other than corticosteroids) or exon skippi[INVESTIGATOR_271480] (includi ng EXONDYS 51®), experimental or otherwise, within 6 months of 
screening.  
9. Has received  any type of gene therapy, cell -based therapy (eg , stem cell transplantation), 
or CRISPR/Cas9  therapy . 
CCI
CCI
CCI
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
29 
CONFIDENTIAL  10. Abnormal laboratory values considered clinically significant : 
11. Patients  with rAAVrh74 antibody titers > 1:400 as determined by  [CONTACT_28745] -linked 
immunosorbent assay  (ELISA ). 
12. Family does not want to disclose patient’s study participation with primary care physician 
and other medical providers.  
4.3. Lifestyle Considerations  
 Every effort should 
be made to collect these samples on the first day of a 2 -day study visit; however, per PI 
[INVESTIGATOR_9106], the samples may be collected during a  1-day study visit.  samples must 
be collected before any fu nctional assessments are performed. Parents  or caregivers should be 
asked to limit patient ’s physical activity level over the 3  days before  a visit  where  samples 
will be collected . 
4.4. Screen Failures  
Screen failures are defined as participant s who consent to participate in the clinical study  but are 
not subsequently randomly assigned to study intervention .  
Individuals who do not meet the eligibility criteria may be rescreened at the Investigator’s 
discretion.   
CCI
CCI
CCI
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
30 
CONFIDENTIAL  5. STUDY INTERVENTION  
Study intervention  is defined as an y investigational intervention (s), glucocorticoid(s) , or placebo 
intended to be administered to a study participant according to the study protocol.  
5.1. Study Intervention(s)  Administered  
 Micro -dystrophin  Placebo  Corticosteroid  
Intervention Name  [CONTACT_105329]-9001 gene vector  Lactated Ringer’s 
solution  Glucocorticoid  
Type  Vector  Placebo  Immunosuppre ssant 
Dose Formulation  IV infusion  IV infusion  Oral or IV  
Dose a 1.33 × 1014 vg/kg   NA 1 mg/kg (prednisone 
equivalent)  
Dosage Level(s)  Single dose  Single dose  Day before infusion and 
continuing for at least 
[ADDRESS_1076865] of the patient  
Route of 
Administration  IV infusion (peripheral 
limb vein)  IV infusion (peripheral 
limb vein)  Oral or IV  
IV = intravenous; NA = not applicable; qPCR = quantitative polymerase chain reaction.  
a For patients who received a dose in this study based on Nationwide Children’s Hospi[INVESTIGATOR_783146], the dose 
used was 2  × 1014 vg/kg which corresponds to 1.33  × 1014 vg/kg as measured by [CONTACT_1034]’s qPCR method using 
a linear standard.  
5.1.1.  Pre-infusion Immunosuppres sants 
The day before the infusion, the patient’s background dose for DMD will be increased to at least 
1 mg/kg of  a glucocorticoid (prednisone equivalent).  
5.1.2.  Post-infusion Immunosuppres sants 
Patients will remain on their stable dose of corticosteroids throughout  Part [ADDRESS_1076866] 1 mg/kg of a glucocorticoid (prednisone equivalent) for at least 
[ADDRESS_1076867] of 
the patient. Additional glucocorticoid may be utilized if GGT level is > 150 U/L or there are 
other clinically significant liver f unction abnormalities following infusion. A tapering dose of 
glucocorticoid will be implemented based on individual patients’ immune response to the 
infusion, assessed by [CONTACT_783169]. This monitoring will be done by [CONTACT_783170]. If there are signs of immune response in specific 
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
31 
CONFIDENTIAL  organ systems like the liver, the Treating Team will closely monitor and make adjustments in 
glucocorticoid dosing.  
5.1.3.  Intravenous  Infusion (Day 1 , Part 1 and Part 2 )  
SRP-9001 or placebo administration will be through a peripheral limb vein.  Administration will 
be performed according to the Site-Specific Pharmacy  and/or Dose Administration  Manual.  
5.1.4.  Post Infusion  Monitoring  
[IP_ADDRESS].  Immediately Following Infusion  
Vital signs will be monitored during and after the infusion according to the Study Operations 
Manual . Concomitant medications and all AEs and SAEs  will also be monitored and documented 
following injection.  
[IP_ADDRESS].  Extended Follow -up 
Patients will return for  clinic  follow -up visits as outlined  in the Schedule of Activities. Patients 
must complete the Week [ADDRESS_1076868] aws may 
occur if the Investigator determines they are necessary for the patients’ safety and wellbeing.   
5.2. Preparation/Handling/Storage/Accountability  
Compliance standards for Biosafety Level [ADDRESS_1076869] 
pharmacy protocol  for handling investigational products similar to SRP -9001 .  
5.3. Measures to Minimize Bias: Randomization and Blinding  
5.3.1.  Establish Patient  Identification Number  
All patients  will be given a unique sequentially assigned patient  identifier . Patients  will be 
identi fied only by [CONTACT_783171].  
5.3.2.  Assignment to a Treatment Group  
This is a double -blind study. Patients who have signed the informed consent and who meet all 
eligibility will be randomized using the IXRS to 1 of the 2 treatment groups  prior to or  on Day -1 
in Part 1 . 
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
32 
CONFIDENTIAL  5.3.3.  Randomization  
Patients will be randomized in a 1:[ADDRESS_1076870] the opportunity 
to receive SRP -9001 in Part 2.  
Randomization will be stratified by [CONTACT_783172] (4 -5 vs 6 -7 years). To ensure 
approximately equal numbers of patients are assigned to the 2 treatment groups (SRP -9001 vs 
placebo) in Part 1, each age group must have a multiple of 4 patients.  
5.3.4.  Blinding/Unblinding  
All patient s and study staff will be blinded  to treatment assignments with the exception of the 
pharmacist  until the last patient com pletes the  visit . The blind of the treatment 
may be broken only in exceptional circumstances, such as when knowledge of the study 
treatment is essential for treating a patient due to an SAE. If time permits, the Investigator must 
contact [CONTACT_783173]. If time does not 
permit, the Investigator may authorize breaking of the blind and then notify the unblinded CRO  
Medical Director. The study treatment information should be disclosed only to personnel who 
need the information for the medical care of the patient. If the study treatment is unblinded, the 
patient number, time, date, and reason for unblinding must be recorded in the study records. 
Study personnel who were unblinded should be ident ified.  Refer to the study unblinding plan for 
further details regarding the unblinding of the study for Part 3.  
Separate study personnel will be designated to conduct functional  assessments and to treat 
patient s in order to protect against possible unblind ing of treatment assignment during regular 
clinical care of patient s. 
The PI [INVESTIGATOR_783151]:  
• An Examining Team  
• A Treating Team  
The Examining Team will be:  
• Composed of physiotherapi[INVESTIGATOR_783152] (NSAA, [ADDRESS_1076871], time to rise from floor, 
and time to ascend 4 steps)  
The Treating Team will be : 
• Composed of clinicians who will be responsible for the following:  
− Administering the study treatment  
− Conducting the patient’s follow -up visits  but not the physical functional 
assessments at those visits per the SoA ( Section  1.3) 
− Review of all clinical and safety laboratory results  
− Glucocorticoid dose adjustments  
− Assessment of AEs, SAEs,  and TEAEs  
− Management of the routine care of the patient  
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
[ADDRESS_1076872] s from the Examining Team will be responsible for conducting the physical 
functional assessments (NSAA, [ADDRESS_1076873], time to rise from 
floor, and time to ascend 4 steps). They will not have access to any patient data and must be 
restricted from having access to  AEs, concomitant medica tions,  laboratory data, and any other 
data that have the potential of revealing the treatment assignment.  The physiotherapi[INVESTIGATOR_783153]/caregivers about their progress 
in the study.  
The Treating  Team members will be responsible for the clinical care of the patient. They will 
manage the study drug infusion, steroid dosing changes, review all laboratory data, assess AEs 
and SAEs, and perform all assessments except for the physical functional assess ments (NSAA, 
10-meter timed test, [ADDRESS_1076874], time to rise from floor, and time to ascend 4 steps). 
The Treating Team will not have access to the data collected by [CONTACT_783174].  
The study will be unblinded once the last patient completes th e  visit ; refer to the 
study unblinding plan for further details.   
5.4. Concomitant Therapy  
To be collected from the time of consent until final study visit, recorded on the case report form 
(CRF ). 
Any medication or vaccine (including over  the counter or prescription medicines, vitamins , 
and/or herbal supplements) that the participant  is receiving at the time of enrollment  or receives 
during the study must be recorded in the CRF.  
If a reaction to the infusion occurs, the Treating Team should tre at the reaction.  The date and 
time of medication administration as well as the name [CONTACT_783200].  
5.4.1.  Rescue Medicine  
There are no specific rescue medications for use in this study  that will turn off SRP-9001  
transgene expression . Cortic osteroid  therapy , at the PI’s discretion, may be used to manage 
possible liver -associated adverse effects of SRP -9001 .  
5.5. Dose Modification  
5.5.1.  Stoppi[INVESTIGATOR_783154] 1 or more Grade 3  (severe)  or 
higher AEs that are unexpected  as related to gene therapy  or DMD . This will include any patient  
death, important clinical laboratory findings, or any severe local complication in the injected area 
related to administration of the study agent.  The findings will be  reported to the data monitoring 
committee ( DMC). If after review by [CONTACT_941] D MC, the recommendation  is made to continue, the 
Sponsor may decide that the study will proceed.  
5.5.2.  Dosing Schedule  
Based on the safety profile of systemic gene delivery clinical trial (Study SRP-9001 -101) for 
DMD  using SRP-[ADDRESS_1076875] 4 patients.  
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
34 
CONFIDENTIAL  5.6. Study  Discontinuation  
If the Sponsor, Investigator, Medical Monitor, DMC, Study Monitor, IRB/IEC, and/or 
appropriate regulatory officials discover conditions arising during the study that indicate the 
study should be halted or that the study center should be terminated, appropriate action may be 
taken after consultation among the Sponsor, Investigator, and ot hers as needed.  
Conditions that may warrant termination of the study or an individual site include, but are not 
limited to, the following:  
• The discovery of an unexpected, serious, or unacceptable risk to subjects enrolled in 
the study  
• A decision by [CONTACT_783175], evaluation, or 
development of the study drug or stop the study  
• Inability of the Investigational site to identify potential subjects for the clinical trial  
• Failure of the Investigator to comply with pertinent regulat ions of IRB/IEC or 
appropriate regulatory authorities  
• Failure of the Investigator to comply with the protocol  
• Submission of knowingly false information from the research facility to the Sponsor, 
the Study Monitor, IRB/IEC, or regulatory authority  
• Insuffici ent adherence or noncompliance with the clinical study protocol and global 
GCP regulations, directives, guidelines, and laws such as the Ph armaceutical and 
Medical Device Act, and the clinical study protocol as applicable.  
Study termination and follow -up w ill be performed in compliance with the conditions set forth in 
International Council for Harmonisation (ICH) E6 on Good Clinical Practice (GCP) as well as 
21 CFR  312.56b and other applicable national/local regulations, which require a Sponsor to 
ensure an  Investigator’s compliance with these requirements and to promptly secure a plan for 
compliance or discontinue shipments of the study drug to the Investigator and end the 
Investigator’s participation in the study.  
If the Sponsor terminates the study for an y reason, if possible, an early termination visit should 
be conducted, as shown in the SoA (Section 1.3). See the SoA (Section 1.3) for data to be 
collected at the time of study discontinuation or termination and for any further evaluations that 
need to be completed.  
5.7. Intervention after the End of the Study  
There will be no intervention following the end of the study.  
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
35 
CONFIDENTIAL  6. STUDY ASSESSMENTS AND PROCEDURES  
• Study procedures and their timing are summarized in the SoA  (Section  1.3). Protocol 
waivers or exemptions are not allowed.  
• Immediate safety concerns should be discussed with the Sponsor immediately upon 
occurrence or awareness to determine if the participant shoul d continue or 
discontinue study intervention.  
• Adherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct.  
• All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The Investigator will maintain a screening log 
to record details of all participants screened and to confirm eligibility or recor d 
reasons for screening failure, as applicable.  
• Procedures conducted as part of the participant’s routine clinical management 
(eg, blood count)  and obtained before signing of the informed consent form ( ICF) 
may be utilized for screening or baseline purpose s provided the procedures met the 
protocol -specified criteria and were performed within the time frame defined in the 
SoA.  
6.1. Efficacy Assessments   
Planned time points for all efficacy assessments are provided in the SoA (Section  1.3). 
6.1.1.  Muscle Biopsy  
A muscle biopsy will be performed at Screening/ Baseline after establishing eligibility . Muscle 
biopsies  will be used to quantify  transgene expression by [CONTACT_783176] 12 in Part 1  
. Additional information can be found in the  
Biopsy Manual.  
6.1.2.  Immunofluorescence Fiber Intensity / Immunofluorescence PDPF  
Muscle biopsies will be used to quantify transgene expression by [CONTACT_31122]  (IF) fiber 
intensity and IF percent dystrophin positive fibers comparing the baseline biops y with both the 
biopsies collected at Week 12 in Part 1 .  
6.1.3.   
 
 
6.1.4.   
 
 
 
  
CCI
CCI
CCI
CCI
CCI
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
36 
CONFIDENTIAL  6.1.5.  Physical Functional  Assessment s 
Efficacy will be measured by [CONTACT_783177] : time to rise from the floor, ascend 
[ADDRESS_1076876] access to information that can disclose 
study treatment, laboratory results, or adverse events.  
The patient’s functional assessments will be videotaped for quality control  and may be viewe d 
by [CONTACT_783178] a quality review. These videos may also be 
used to demonstrate any functional outcomes related to the study drug and shared at scientific 
meetings and/or with regulatory authorities . 
[IP_ADDRESS].  Time to Rise from the Floor  
This a ssessment is performed as a part of the NSAA. It measures the time taken to rise from 
supi[INVESTIGATOR_144658].  
[IP_ADDRESS].  Ascend 4 Steps  
This assessment  measures the time taken to climb 4 steps.  
[IP_ADDRESS].  North Star Ambul atory Assessment  
The NSAA is a healthcare provider  administered scale that rates patient performance on various 
functional activities  (Mazzone 2010 ). During this assessment, patients will be asked to perform 
17 different functional activities, including a 10 -meter walk/run, rising from a sit ting position  to 
standing  position , standing on 1 leg, climbing a box step, descending a box step, rising from 
lying to sitting, rising from the floor, while supi[INVESTIGATOR_783155] , standing on heels, and 
jumpi[INVESTIGATOR_007].  
[IP_ADDRESS].  10-meter  Timed Test  
This assessment m easures the  time needed to move 10 meters.  
[IP_ADDRESS].  100-meter Timed Test  
This assessment measures the  time needed to move 100 meters.  
6.2. Safety Assessments  
Planned time points for all safety assessments are provided in the SoA  (Section  1.3). 
Safety parameters evaluated during the conduct of the study include AEs, SAEs, TEAEs , clinical 
laboratory values,  antibody tite rs, vital signs,  ECGs, ECHOs,  physical examination findings, and 
use of concomitant medications.  
6.2.1.  Physical Examination s 
Physical examinations  will be conducted at the time points specified in  the SoA ( Section  1.3). 
Physical examinations will include examination of general appearance, head, ears, eyes, nose, 
and throat, heart, chest, abdomen, skin, lymph nodes, extremities, musculoskeletal, and 
neurological systems.  
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
37 
CONFIDENTIAL  Any physical examination finding assessed as clinically significant should be recorded as an AE 
or SAE. If SAE criteria are met, the event should be recorded and reported according to the SAE 
reporting process (see  Section  6.3). 
6.2.2.  Vital Signs  
Vital signs (blood pressure, heart rate, respi[INVESTIGATOR_1516], and oral temperature) will be measured at the 
time points specified in the SoA ( Section  1.3). 
Vital signs including blood pressure, heart rate, respi[INVESTIGATOR_697], and temperature will be 
performed after study treatment infusion according to the Study Operations Manual.   
Any vital signs assessed as clinically significant should be recorded as an AE or SAE. If SAE 
criteria are met, the event should be recorded and reported according to the SAE reporting 
process (see  Section  6.3). 
6.2.3.  Electrocardiograms  and Echocardiograms  
Single ECGs will be obtained at the time points specified in  the SoA ( Section  1.3) using an ECG 
machine that automatically calculates the heart rate and measures PR, QRS, and QT  intervals . 
ECGs will be performed at a consistent time of day throughout the study. The Investi gator , or 
designee, will review the results of the ECG report and determine if the findings are clinically 
significant.  
A standard 2 -dimensional ECHO will be obtained at the time point s specified in the SoA 
(Section  1.3). Echocardiograms  will be performed at a consistent time of day throughout the 
study and before any invasive procedures (eg, blood sampling, study drug infusion, or biopsy).  
The ECHO will be reviewed and interpreted by [CONTACT_783179].  Left 
ventricular eject ion fraction  will be noted.  The Investigator, or designee, will review the results 
of the ECHO report and determine if the findings are clinically signi ficant.  
Clinical significance is defined as any variation in assessment results that has medical relevance 
resulting in an alteration in medical care.  If clinically significant deterioration from baseline 
levels is noted, the Investigator will continue to  monitor the patient with additional assessments 
until:  
• Values have reached normal range and/or baseline levels; or  
• In the judgment of the Investigator together with the Sponsor’s Medical Monitor, 
abnormal values  are assessed to be not related to the adm inistration of study treatment 
or other protocol -specific procedures, and additional assessments are not medically 
indicated.  In the judgment of the Investigator, an unexplained laboratory abnormality 
that could potentially lead to a poor outcome should re sult in interruption of 
treatment.  
If assessed as clinically significant, the event should be recorded as an AE or SAE as required in  
Section  6.3. 
6.2.4.  Clinic al Safety Laboratory Assessments  
The following routine clinical laboratory tests will be performed at the time points specified in 
the SoA ( Section  1.3). Samples will be collected and processed according to  the local laboratory 
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
38 
CONFIDENTIAL  procedures, the Study Operations Manual, and/or  the Central Laboratory Manual provided for 
the study : 
Chemistry:  Sodium, chloride, potassium, carbon dioxide , glucose, creatinine, 
blood urea nitrogen, total protein,  albumin,  total bilirubin, alkaline 
phosphatase, amylase, ALT,  AST, GGT, lactate dehydrogenase , 
C-reactive protein,  and serum cystatin  C, complement  (CH50, 
C3, C4, and factor B ), and GLDH  
Note: CH50 may be collected and analyzed by [CONTACT_977]; 
however, C3, C4, and factor B will be collected and analyzed by [CONTACT_783180].  
Note : The  GLDH assay will be performed by a central laboratory and 
only at clinic visits.  
Hematology:  Red blood cells, total WBCs, hemoglobin, hematocrit, neutrophils, 
lymphocytes, monocytes, eosinophils, basophils, platelets, and 
abnormal cells  
Coagulation Screen:  Prothrombin time , partial thromboplastin time , and international 
normalized ratio   
  
 
Urinalysis:  pH, specific gravity, protein, glucose, ketones, cytology, and 
hemoglobin  
Any laboratory abnormality deemed clinically significant by [CONTACT_783181]. A clinically significant abnormality is an abnormality confirmed by [CONTACT_15013], that 
in the judgment of the Investigator warrants a change in mana gement. This alteration may 
include monitoring the laboratory test further, initiating other diagnostic tests or procedures, 
changing ongoing treatment, or administering new treatment (s).  
Whenever possible, the underlying medical diagnosis (eg, anemia) sh ould be recorded as the AE 
term. Repeated additional tests and/or other evaluations required to establish the significance and 
etiology of an abnormal result should be obtained when clinically indicated.  
Patient s enrolled under this clinical protocol are expected to present clinically with adverse 
events related to natural progression of the disease.  The draft guidance entitled “Duchenne 
Muscular Dystrophy Developi[INVESTIGATOR_783156]” 
(https://www.regulations.gov/document?D= FDA -2014 -D-1264 -0002 ) provides the basis of 
expected disease -related AEs. The expectedness of all AEs will be determined according to the 
most recent versions of the Investigator’s Brochure ( Section  [IP_ADDRESS] ). 
Asymptomatic elevations in transaminases are a feature of Duchenne muscular dystrophy, as 
they are related to release of AST and ALT from muscle tissue and correlate with levels of CK. 
These are a fe ature of the disease itself. Levels of AST and ALT up to 10 × the ULN  are expected 
to be seen at Baseline and  are not indicative of muscle or liver injury. Elevated AST/ALT levels 
are thus not exclusionary for enrollment and , depending on circumstances,  will not be recorded 
as adverse events during the course of the trial.  
CCI
CCI
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
39 
CONFIDENTIAL  6.2.5.  Safety Monitoring  
[IP_ADDRESS].  Safety Monitoring for Liver Chemistry Tests  
Liver chemistry tests need to  be monitored as specified in the SoA (Section  1.3). Initial abnormal 
liver chemistry test result(s) need to  be confirmed if:  
• GGT or GLDH is × ULN at any time during the study  
• AST or ALT measurement is × baseline value if the baseline  value is >ULN ;  
Patients with confirmed liver chemistry test results (as above) should  have their liver tests  
 
 retested at a minimum of  and additional testing 
beyond that is at the discretion of the Investigator . Frequency of retesting can decrease to once a 
week or less if abnormalities stabilize  and the patient is asymptomatic . 
Additional Investigations  
Patients with confirmed abnormal liver chemistry test results (as above) are recommended to 
have the following evaluations performed:  
• Obtaining a more detailed history of symptoms and prior or concurrent diseases  
• Obtaining a history of concomitant drug use (including nonprescription medications 
and herbal and dietary supplement preparations), alcohol use, recreational drug use, 
and special diets  
• Ruling out acute viral hepatitis types A, B, C, D, and E; autoimmune hepatitis; 
Non-Alcoholic Steato Hepatitis; h ypoxic/ischemic hepatopathy; and biliary tract 
disease  
• Consideration of other viral illnesses that have been associated with hepatitis (eg, 
Epstein -Barr virus, cytomegalovirus, Human Herpesvirus 6 ) 
• Obtaining a history of exposure to environmental chemical  agents  
Additional liver evaluations, including  
 may be performed at the discretion of the Investigator, in 
consultation with the Sponsor Medical Monitor.  
Refer to Section  [IP_ADDRESS]  for the list of  adverse events of special interest ( AESIs ) related to liver 
chemistry tests.  
[IP_ADDRESS].  Safety Monitoring for Hypersensitivity and Comple ment -Mediated Reactions  
Patients will be monitored for hypersensitivity and complement -mediated reactions as follows:  
• Hypersensitivity:  Patients will be monitored for occurrence of allergic reactions by 
[CONTACT_783182] (Section  1.3). Patients will be instructed to 
promptly report any signs or symptoms of fever or constitutional symptoms that may 
arise during the study, and t he Investigator needs to closely evaluate all potential 
causes, including concomitant illness.  
CCI
CCI
CCI
CCI
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
40 
CONFIDENTIAL  • Complement -mediated reactions:  Patients will be monitored for occurrence of 
complement -mediated reactions by [CONTACT_783182] 
(Section  1.3). In addition to monitoring AEs, routine laboratory monitoring for 
complement levels (CH50, C3, C4, and factor B) will be performed as outlined in the 
SoA (Section  1.3). 
Additional Investigations  
• Hypersensitivity:  Patients who experience significant or persistent constitutional 
symptoms, includ ing any Grade ≥ 3 hypersensitivity reactions, need to be discussed 
with the Sponsor Medical Monitor to determine whether additional monitoring or 
laboratory tests are required. Additional evaluations including  
 
 may be performed at the discretion of the 
Investigator in consultation with the Sponsor Medical Monitor.  
• Atypi[INVESTIGATOR_151258] (aHUS):  Patients diagnosed with aHUS need to 
be discussed with the Sponsor Medical Monitor to determine additional monitoring 
and laboratory testing. Additional evaluations including  
 
 
 
 
 
 
 may be performed at the discretion of the 
Investigator in  consultation with the Sponsor Medical Monitor.  
Refer to Section  [IP_ADDRESS]  for the list of AESIs related to hypersensitivity.  
[IP_ADDRESS].  Safety Monitoring for Platelet Count Results  
Platelet counts will be monitored according to the SoA (Section  1.3). Patients with a confirmed 
occurrence of platelets  need to  have the following evaluations performed:  
•  
•  
•  
 
•  
CCI
CCI
CCI
CCI
CCI
CCI
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
41 
CONFIDENTIAL  Additional Investigations  
Additional platelet evaluations for confirmed, unexplained significant platelet count reductions, 
 
 
 may be 
performed at the discretion of the Investigator in consultation with the Sponsor Medical Monitor.  
Refer  to Section  [IP_ADDRESS]  for the list of AESIs related to thrombocytopenia . 
[IP_ADDRESS].  Safety Monitoring for Rhabdomyolysis  
Rhabdomyolysis will be monitored by [CONTACT_783183] (Section  1.3). Patients who have confirmed heme+ dipstick urinalysis need to  be 
evalua ted by [CONTACT_783184]:  
Additional Investigations  
In case of rhabdomyolysis, myoglobinuria, or chromaturia, patients will need to have evaluations 
of  
 
 these 
evaluations should be undertaken at the discretion of the Investigator.  
In addition, Investigators should obtain a more detailed history of symptoms, preceding activity 
and hydration status, concomitant drug use, and recent or concurr ent infections. Additional 
evaluations,  may 
be performed at the discretion of the Investigator in consultation with the Sponsor Medical 
Monitor.  
Refer to Section  [IP_ADDRESS]  for the list of AESIs related to rhabdomyolysis.  
6.2.6.   
 
 
  
 
 
 
 
 
  
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
42 
CONFIDENTIAL   
 
 
  
6.2.7.   
 
 
 
  
 
6.2.8.   
 
 
 
 
 
6.3. Adverse Events  and Serious Adverse Events  
6.3.1.  Collection of Adverse Events  
Over  the entire duration of the study, site personnel will ensure that all AEs are recorded 
appropriately. If an AE occurs, the primary concern is for patient safety, and the Investigator will 
use his/her judgment and expertise to determine the appropriate cou rse of action.  
All AEs from the time of informed consent through the last follow -up visit will be recorded in 
each enrolled  patient’s CRF.  For consented patients who are found to be ineligible for the study 
during the Screening period and are not enrolled (ie, Screening failures), only SAEs  will be 
collected . 
If, at any time after the patient has completed participation in the study, the Investigator or study 
staff becomes aware of an SAE that the Investigator believes is possibly/probably or definitely 
related to the  investigational product  (IP) or is possibly/probably or definitely related to a study 
procedure, then the event and any known details must be reported promptly to the Sponsor.  
6.3.2.  Definition of Adverse Events  
[IP_ADDRESS].  Adverse Event  
An AE is any untoward medical occurrence in a clinical trial participant, which does not 
necessarily have a causal relationship with the investigational drug. An AE can, therefore, be any 
unfavorable and unintended symptom, sign, disease, condition, or tes t abnormality that occurs 
during or after administration of an IP whether or not considered related to the IP.  
CCI
CCI
CCI
CCI
CCI
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
43 
CONFIDENTIAL  Adverse events include:  
• Symptoms described by [CONTACT_783185].  
• Test abnormalities (laboratory tests, ECG, X -rays, etc.) that result in an alteration in 
medical care (diagnostic or therapeutic).  
Abnormalities present at Screening are considered AEs only if they reoccur after resolution or 
worsen during the AE collection period.  
[IP_ADDRESS].  Serious Adverse Event s 
An SAE is defined as any AE that results in any of the following:  
• Death : The patient died as the result of the event.  
• Life-threatening  event : Any AE that places the patient, in the view of the 
Investigator or Sponsor, at immediate risk of death from the AE as it occurred, 
ie, does not include an AE that had it occurred in a more severe form, might have 
caused death.  
• Required or prolonged inpatient hospi[INVESTIGATOR_059] : The AE resulted in 
hospi[INVESTIGATOR_376639]. Since hospi[INVESTIGATOR_783157], only hospi[INVESTIGATOR_783158], based on Investigator judgment, will be considered prolonged 
hospi[INVESTIGATOR_602].  
• Persistent or significant disability/incapacity : An AE that results  in persistent or 
significant disability or disruption of a person’s ability to conduct normal life 
functions.  
• Important medical events : An AE that may not result in death, be life-threatening , 
or require hospi[INVESTIGATOR_12475], base d upon appropriate 
medical judgment, the event may jeopardize the patient and may require medical or 
surgical intervention to prevent one of the outcomes listed above.  
[IP_ADDRESS].  Adverse Event s of Special Interest  
An AESI is any AE (serious or nonserious) that is of  scientific and medical interest specific to 
the study treatment for which ongoing and/or rapid communication by [CONTACT_14538].  See Section  [IP_ADDRESS]  for the list of AESI s for this study.  
6.3.3.  Classification of Adverse Events  
Each AE whether serious or non -serious will be classified by [CONTACT_783186].  
[IP_ADDRESS].  Relationship to Investigational Product  
For each AE, the Investigator will determine whether there is a reasonable likelihood that the AE 
may have been caused by [CONTACT_783187]:  
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
44 
CONFIDENTIAL  Unrelated:  The event is clearly not related  to the stud y treatment . 
Possibly/probably related:  The event could be related/is likely to be related  to the 
study treatment . 
Definitely related:  The event is clearly related  to the study treatment . 
[IP_ADDRESS].  Relationship to Study Procedures  
For each AE the Investigator will determine whether there is a reasonable possibility that the AE 
may have been caused by [CONTACT_783188]:  
Unrelated:  The event is clearly not related  to the study procedures . 
Possibly/probably related:  The event could be related/is likely to be related  to study 
procedures . 
Definitely related:  The event is clearly related  to the study procedures . 
[IP_ADDRESS].  Relationship to Underlying Disease  
For each AE the Investigator will determine whether there is a reasonable possibility that the AE 
may be related to the underlying disease according to the categories below:  
Unrelated:  The event is clearly not related  to the underlying disease  
Possibly/probably related:  The event could be related/is likely to be related  to the 
underlying disease  
Definitely related:  The event is clearly related  to the underlying disease  
Events of disease progression may be considered AEs, based on the Investigator’s discretion.  
[IP_ADDRESS].  Severity of Adverse Events  
Note that severity is not the same as “seriousness ”. 
The Investigator will assess the severity of all AEs as Mild, Moderate, or Severe, based on the 
following definitions:  
Mild:  The event does not interfere with the patient’s usual activities.  
Moderate:  The event interferes with the patient’s  usual activities.  
Severe:  The event prevents the patient from undertaking their usual activities and 
requires therapeutic intervention or cessation of the study treatment.  
[IP_ADDRESS].  Outcome  
An o utcome describes the status of the AE. The Investigator will provide information regarding 
the patient outcome of each AE. Outcome categories will include recovered, recovered with 
sequelae, not recovered, fatal, and unknown.  
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
45 
CONFIDENTIAL  [IP_ADDRESS].  Action Taken Regarding the Investigational Product  
The Investigator will provide information regard ing the action taken with respect to the study 
treatment in response to the AE. Categories for action taken regarding study treatment will 
include none, drug interrupted, drug withdrawn, and not applicable.  
[IP_ADDRESS].  Expectedness of an Adverse Event  
The expectedness  of all AEs will be determined  according to the most recent versions of the 
Investigator’s Brochure.  
[IP_ADDRESS].  Suspected Unexpected Serious Adverse Reactions  
Susp ected unexpected serious a dverse reactions (S[LOCATION_003]Rs) will be reported within the required 
timelines  in an unblinded fashion to regulatory authorities and Institutional Review Board 
(IRB)/Independent Ethics Committee ( IEC) per the requirements of the concerned competent 
authorities. S[LOCATION_003]Rs will also be reported in a blinded fashion to study Investigators  
6.3.4.  Recording of Adverse Events  
All AEs from the time of informed consent/assent through  the last follow -up visit will be 
recorded in each enrolled patient’s CRF. For patients who are found to be ineligible for the study 
during the Screening period and are not enrolled (ie, Screening failures), only SAEs  will be 
recorded . 
Information should include: a concise description of the event; date of event onset and 
resolution; determination of seriousness, severity, corrective treatment  (if any) , outcome, and 
relationship to IP or study procedure or underlying disease; and any action taken will be 
recorded. Resolution occurs when the patient has returned to his baseline state of health or 
further improvement or worsening of the event is not expec ted. 
Whenever possible, a diagnosis will be recorded as an AE, rather than symptoms or isolated 
laboratory abnormalities related to that diagnosis. Several symptoms or laboratory results that are 
related to the same diagnosis can thus be part of the same A E. A medical or surgical procedure is 
not an AE; rather the condition leading to the procedure should be recorded as the AE. Similarly, 
death is not an AE, but is rather the outcome of the AE(s) that resulted in death. If the AE(s) 
leading to death are not  known, then death must be reported as an AE. All AEs will be followed 
until the resolution of AE, completion of the patient’s study participation, or study termination, 
whichever occurs first. SAEs will be followed until resolution or until the condition stabilizes or 
returns to baseline status.  
6.3.5.  Reporting Serious Adverse Events  
It is the responsibility of the Investigator that reporting is done adequately. In order to meet 
Regulatory reporting timelines, the study site is obligated to report any SAE(s) to the Sponsor or 
designee immediately and no later than [ADDRESS_1076877] one of the criteria for seriousness . 
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
46 
CONFIDENTIAL  6.3.6.  Special Situations  
[IP_ADDRESS].  Overdose  
Refer to Section  6.4 for the definition of treatment overdose. An overdose is not an AE. An 
overdose will be reported even if it does not result in an AE. An overdose will be recorded on the 
Clinical Trial Safety Report ing Form and sent to the Sponsor or designee within 24  hours.  
[IP_ADDRESS].  Adverse Events of Special Interest  
All AESIs need to be reported to the Sponsor via email to  within [ADDRESS_1076878]:  
Hepatotoxicity  
Hypersensitivity  
Thrombocytop enia 
Rhabdomyolysis  
[IP_ADDRESS].  Death  
Death is an outcome of an event. All causes of death are SAEs. In the event of death, every effort 
should be made to obtain a death certificate and if possible, an autopsy report. If the cause of 
death is unknown, death will be recorded as the event.  
[COMPANY_003]
CCI
CCI
CCI
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
47 
CONFIDENTIAL  [IP_ADDRESS].  Unblinding due to a Medical Emergency  
In the event of a medical emergency , such as when  knowledge of the patient ’s treatme nt 
assignment is essential for treating a patient due to an SAE , the Investigator has the option to 
unblind treatment assignment through the I XRS . If time permits, the Investigator must contact 
[CONTACT_783189] e patient. If time does not 
permit, the Investigator may authorize breaking of the blind, and then notify the unblinded CRO  
Medical Director.  
The reasons for unblinding  and the study personnel who were unblinded  must be noted in the 
source documentation. T he Investigator must not disclose information about treatment 
assignment to anyone who does not need the information for patient care. Disposition of patients 
who become unblinded due to medical emergency will be determined following discussion with 
the Sp onsor.  
The study will be unblinded once the last patient completes the  visit ; refer to the 
study unblinding plan for further details.  
6.3.7.  Responsibilities of the Investigator  
The responsibilities of the Investigator include but are not limited t o the following:  
• Monitor and record all AEs . 
• Determine seriousness, severity, and relationship to IP and/or study procedure and/or 
underlying disease . 
• Determination of the onset and end date of each event . 
• Provide initial report on all SAEs within [ADDRESS_1076879] knowledge to the Sponsor 
via email to  or designee . 
• Provide follow -up information on SAEs in a timely and proactive manner . 
• Respond to queries regarding AEs and SAEs in a timely manner . 
• Ensure source documentation for all AEs are accurate and complete . 
• Ensure that the study is conducted as defined in this protocol.  
Investigators may also report improvement of pre -existing DMD conditions or unexpected 
therapeutic responses.  
6.3.8.  Responsibilities of the Sponsor  
The responsibilities of  the Sponsor ( Sarepta  and designees)  include , but are not limited to the 
following:  
• Training of Investigator and site staff on AE/SAE definitions, safety assessments, and 
site obligations related to safety monitoring and reporting of AE/SAEs . 
• Accurate and timely  reporting of S [LOCATION_003]Rs  to all applicable regulatory bodies, clinical 
trial Investigators , and other parties as appropriate and required within the regulated 
timelines.  
CCI
[COMPANY_003]
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
48 
CONFIDENTIAL  • Ensuring accurate recording of AEs and SAEs .  
• Notification of expedited S[LOCATION_003]Rs to si tes. 
• Annual safety reporting to regulatory authorities and IRBs/IECs according to regional 
requirements . 
6.4. Treatment Overdose  
For this study, any dose of SRP-9001   for a specific patient  
will be considered an overdose.  
There  is no  recommend ed specific treatment for an overdose . 
In the event of an overdose, the Investigator should:  
1. Contact [CONTACT_2024] ’s unblinded Medical Director immediately.  
2. Closely monitor the participant for any AE/SAE and laboratory abnormalities until  
resolution.  
3. Document the quantity of the excess dose as well as the duration of the overdose on the 
Overdose Form and send to the Sponsor immediately. The overdose should also be 
entered in the CRF.  
4. Provide appropriate medical care to patient based on cli nical judgement.  
Decisions regarding dose interruptions or modifications will be made by [CONTACT_783190] h the CRO ’s unblinded Medical Director  based on the clinical evaluation of the 
participant.  
6.5. Pharmacokinetics  
Pharmacokinetic  parame ters are not being evaluated in this study.  
6.6. Pharmacodynamics  
Creatine kinase levels will be measured at time  points according to the SoA ( Section  1.3). 
Muscle biopsies will be performed at Screening/Baseline  and at Week 12  in Part 1  
. 
6.7.  
CCI
CCI
CCI
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
49 
CONFIDENTIAL  6.7.1.   
6.7.2.   
6.8. Biomarkers  
The collection of muscle biopsy samples  to assess micro -dystrop hin 
 will be obtained; however, they are considered efficacy endpoints and described 
in Section  6.1.  
6.9.  
6.9.1.   
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
50 
CONFIDENTIAL  6.9.2.   
 
 
 
 
 
CCI
CCI
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
51 
CONFIDENTIAL  7. STATISTICAL CONSIDERATIONS  
7.1. Statistical Hypotheses  
The study has 2 primary endpoints: change in quanti ty of micro -dystrophin protein expression 
from Baseline to Week 12 (Part 1) as measured by [CONTACT_783191] 48  (Part 1) . Each  primary endpoint will be tested for  statistical 
significan ce based on a multiplic ity-adjusted testing procedure  that will  control the overall 
Type  I error rate at a 2 -sided level of 0.05 .  
 
 
 
 
 Additional details will be  specified in the Statistical Analysis Plan ( SAP). 
The statistical analyses of endpoints in Part [ADDRESS_1076880].  
The statistical hypotheses for other micro -dystrophin expression endpoints can be stated in a 
similar manner as those for change in quantity of micro -dystrophin protein expression from 
Baseline to Week 12  as measured by [CONTACT_27187] . 
For the primary  efficacy endpoint of change in NSAA total score  from Baseline to Week  48 
(Part  1), the null hypothesis is that the population means for the [ADDRESS_1076881].   
The statistical hypotheses for secondary endpoints on physical function can be stated in a similar 
manner as those for change in  NSAA total score  from Baseline to Week 48  (Part  1). 
7.2. Sample Size Determination  
A dramatic treatment difference is expected  for the primary endpoint of change from Baseline 
to Week 12 in quantity of micro -dystrophin protein expression as measured by [CONTACT_27187] . 
Therefore, the  sample size is based on the power for the primary  efficacy endpoint  of change 
in NSAA  total score from Baseline to Week 48  (Part 1)  with Type I error of 0.05 (2 -sided), 
assuming the alpha allocated for the other primary endpoint will be recycled .  
 
 
 
 
 
CCI
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
52 
CONFIDENTIAL  7.3. Analysis Populations  
For purposes of statistical analys es, the following analysis populations are defined:  
Population  Description  
Intent -to-Treat (ITT)  All randomized patient s who received study treatment  during Part [ADDRESS_1076882] the study results . Eligibility for 
the Per -Protocol population will be determined prior to breaking the 
study blind.   
Safety  All patient s who received study treatment  during Part 1 or Part 2 , with 
treatment group designated according to the treatment  that they 
actually received.   
7.4. Statistical Analyses  
An SAP will be developed and finalized before database lock and unblinding of the study data. It 
will describe the details of the statistical analyses. This section is a summary of the planned 
statistical analyses of the primary and second ary endpoints as well as the safety analyses.   
7.4.1.  Efficacy Analyses  
The study has 2 primary endpoints : change in quantity of micro -dystrophin protein expression 
from Baseline to Week 12  (Part 1)  as measured by [CONTACT_783191] 48  (Part 1) . Each primary endpoint will be tested for statistical 
significance based on the multiplicity -adjusted testing procedure  that will control the overall 
Type I error at a 2 -sided level of 0.05.  
Endpoint  Statistical Analysis Methods  
Primary   For the primary endpoint of change in  quantity of micro -dystrophin protein 
expression from Baseline to Week 12 (Part 1) as measured by [CONTACT_27187], 
summary statistics will be provided by [CONTACT_783192], Week 12 , and 
change from Baseline to Week 12  for quantity of micro -dystrophin protein 
expression as measured by [CONTACT_27187].   
 
 
 
 
 
  
For the primary efficacy endpoint of change in NSAA total score from Baseline to 
Week 48 (Part 1), summary statistics will be provided by [CONTACT_783193], each post -Baseline visit, and change from Ba seline to each post -Baseline 
visit.  
A mixed  model with repeat measures or another test deemed appropriate, to be 
specified in the SAP, will be performed to compare the treatment groups for change 
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
53 
CONFIDENTIAL  Endpoint  Statistical Analysis Methods  
in NSAA total score from Baseline to Week 48 (Part 1). The superiority of SRP -[ADDRESS_1076883] achieves statistical significance based on 
the multiplicity -adjusted testing procedure that will be specified in the SAP.  
Secondary   The secondary endpoints will be analyzed  using similar statistical methods as the 
primary endpoints, as appropriate, with details specified in the SAP.  
   
7.4.2.  Safety Analyses  
Four sets of safety analyses will  be performed: (1) Part 1, this will provide summaries of safety 
endpoints in a side -by-side comparison between the two treatment groups that should be similar 
at Baseline;  
 
 (3) Part 1 , this will provide summaries of safety endpoints 
in a side -by-side comparison between the two treatment groups thro ugh Part 1 ; 
(4) Time since  SRP-9001 treatment , this will provide summaries of safety endpoints across all 
patients who received SRP -9001  in either Part 1 , starting from the time of SRP -9001 
infusion and continue through the end of the study.  
Endpoint  Statistical Analysis Methods  
Safety:  TEAEs,  
and SAEs  Adverse events will be coded by [CONTACT_67503].  
TEAE s include all AEs that occurred or increased in severity since the study 
treatment.  A treatment -related TEAE will be defined as a TEAE that the Investigator 
consider ed possibly/probably or definitely related to the study treatment.  
TEAEs will be summarized by [CONTACT_783194] s who reported TEAEs, with groupi[INVESTIGATOR_783159]. SAEs  will be summarized in the same way. TEAEs will also be summarized by 
[CONTACT_1570], with groupi[INVESTIGATOR_783160] , preferred term , and severity. 
Further, treatment -related TEAEs will be summarized in t he same way as TEAEs.   
Safety:  Clinical 
laboratory 
assessments  Clinical laboratory variables will be presented in [ADDRESS_1076884], change from Baseline to each scheduled assessment will be summarized 
descriptively by [CONTACT_1570]. Baseline will be defin ed as the value of the clinical 
laboratory variable obtained immediately before dosing of study drug (Day -1 for 
Part 1 and Day -1 for Part 2 ). For Part 1, if Day -1 value is unavailable, the value 
obtained at the Screening Visit will be used.  
Second, trea tment -emergent potentially clinically significant (PCS) laboratory values 
will be identified. Criteria for PCS laboratory values will be defined in the SAP. 
Treatment -emergent PCS laboratory values will be defined as post -Baseline PCS 
laboratory values for  patient s whose baseline value for the same laboratory variable 
did not meet the PCS criteria.  The number and percentage of patient s with a 
treatment -emergent PCS laboratory value will be summarized by [CONTACT_783195].  
Third, the number and percentage of patient s with abnormal, clinically significant 
laboratory values (per Investigator judgment) will be summarized by [CONTACT_783196].  
CCI
CCI
CCI
CCI
CCI
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
[ADDRESS_1076885] for multiplicity to control the 
overall Type I error rate at a 2 -sided level of 0.05.   
7.5.1.  Interi m Analysis at Week 12 in Part 1  
An interim analysis for micro -dystrophin expression will be performed after the blinded assays 
for micro -dystrophin expression for Baseline and Week 12 (Part 1) have been completed. Unless 
an unexpected outcome occurs at the  interim analysis, there is no plan to change the conduct of 
the study after the interim analysis. A procedure will be put in place prior to unblinding of any 
personnel to micro -dystrophin expression data to ensure that the study continues to be conducted 
as a double blinded study after this interim analysis.  
7.5.2.  Interim Analysis at the Completion of Part [ADDRESS_1076886] prior to unblinding of 
a limited number of personnel to ensure that the study continues to be conducted as a double 
blinded study after this interim analysis.  
7.5.3.   
 
 
7.5.4.  Interim Analysis Based on Regulatory Interactions  
An additional interim analysis may be performed based on regulatory interactions. The decision 
to perform this inte rim analysis may take into account information external to this study and/or 
blinded study data review. If this interim analysis is to be performed  during Part [ADDRESS_1076887] prior to this interim analysis to ensure that the study continues to 
be conducted as a double blinded study after this interim analysis.  
7.6. Data Monitoring  Committee  
An independent DMC will be established to periodically review the safety data of this study and 
provide recommendation s to the Sponsor. The DMC will operate under a DMC  charter to be 
approved by [CONTACT_783197] .  
CCI
CCI
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
55 
CONFIDENTIAL  8. DISCONTINUATION OF STUDY INTERVENTION AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL  
8.1. Discontinuation of Study Intervention  
Participants will receive a single -dose of study tr eatment  in Part 1 and Part 2  of the study ; 
therefore , discontinuations from the study intervention are not anticipated.  
8.2. Participant Discontinuation/Withdrawal from the Study  
• A participant may withdraw from the study at any time at his own  or legal guardian ’s 
request or  may be withdrawn at any time at the discretion of the Investigator for 
safety, behavioral, compliance, or administrative reasons. This is expected to be 
uncommon.  
• At the time of discontinuing from the study  or if the sponsor terminates the st udy for 
any reason , if possible, an early termination visit should be conducted, as shown in 
the SoA  (Section  1.3). See the SoA (Section  1.3) for data to be collected at the time of 
study discontinu ation or termination and for any further evaluations that need to be 
completed.  
• If the participant  (or legal guardian)  withdraws consent for disclosure of future 
information, the Sponsor may retain and continue to use any data collected before 
such a withd rawal of consent.  
• If a participant withdraws from the study, he (or legal guardian) may request 
destruction of any samples taken and not tested, and the Investigator must document 
this in the site study records.  
8.3. Lost to Follow -up 
A participant  will be cons idered lost to follow -up if he repeatedly fails to return for scheduled 
visits and is unable to be contact[CONTACT_9298].  
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit:  
• The site must attempt to contact [CONTACT_2299]  (or if applicable, the legal guardian 
who signed the informed consent on behalf of the participant)  and reschedule the 
missed visit as soon as possible and counsel the participant (or if applicable, the legal 
guardian who  signed the informed consent on behalf of the participant) on the 
importance of maintaining the assigned visit schedule and ascertain whether or not 
the participant wishes to and/or should continue in the study.  
• Before a participant is deemed lost to follo w up, the Investigator or designee must 
make every effort to regain contact [CONTACT_6635] (or if applicable, the legal 
guardian who signed the informed consent on behalf of the participant) (where 
possible, 3 telephone calls and, if necessary, a cer tified letter to the participant’s last 
known mailing address or local equivalent methods). These contact [CONTACT_97254]’s medical record.  
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
56 
CONFIDENTIAL  • Should the participant continue to be unreachable, he/she will be considered to hav e 
withdrawn from the study.  
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
57 
CONFIDENTIAL  9. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  
9.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  
9.1.1.  Clinical Monitoring of the Study  
The study will be monitored in compliance with the relevant parts of 21 Code of Federal 
Regulations ( CFR ) and according to the Internation al Council on Harmonisation ( ICH) Good 
Clinical Practices ( GCP ) Guidelines. The procedures outlined in the protocol an d case report 
forms will be carefully reviewed by [CONTACT_978] [INVESTIGATOR_783161]. No deviations from the protocol shall be made except in 
emergency situations where alternative treatment i s necessary for the protection, proper care and 
wellbeing of patient s. 
9.1.2.  Regulatory and Ethical Considerations  
• This study will be conducted in accordance with the protocol and with the following:  
− Consensus ethical principles derived from international guidel ines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences International Ethical Guidelines  
− Applicable ICH GCP Guidelines  
− Applicable laws and regulations  
• The protocol, protocol amendments, ICF, Investigator B rochure, and other relevant 
documents (eg, advertisements) must be submitted to an IRB/IEC by [CONTACT_468849]/IEC before the study is initiated.  
• Any amendments to the protocol will require IRB/IEC approval before 
implementation of changes made to the study design, except for changes necessary 
to eliminate an immediate hazard to study participants.  
• The Investigator will be responsible for the following:  
− Providing written summaries of the status of the study to the IRB/ IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/IEC  
− Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures  
− Providing oversight of the conduct  of the study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 
536/2014 for clinical studies (if applicable), and all other applicable local 
regulations  
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
58 
CONFIDENTIAL  9.1.3.  Financial Disclosure  
Investigators and sub -Investigators will provide the Sponsor with sufficient, accurate financial 
information as requested to allow the Sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigator s and 
sub-Investigators  are responsible for providing information on financial interests during the 
course of the study and for 1 year after completion of the study.  
9.1.4.  Informed Consent Process  
Legally effective and properly executed written informed consent,  in compliance with 
21 CFR  50 and the ICH guidelines, will be obtained from each patien t, or legal guardian 
where  applicable,  before the patient  is entered into the trial or before any unusual or non -routine 
procedure is performed that involves risk to the patient . The informed consent will be signed 
prior to study procedures and will require IRB approval. Attention will be directed to the basic 
elements that are required for incorporation into the informed consent under U nited States 
Federal Regulations for Protection of Human Subjects [21CFR 50.25(a)] . The final 
IRB-approved document as well as any subsequent approved modified consent document(s)  
must be provided to correspondent agencies for regulatory purposes . If new information related 
to the study arises, patient s, or legal guardians where applicable,  will be asked to sign a revised 
document . Signed consent forms will remain in each patient 's research chart and will be available 
for verification by [CONTACT_9534] . Patient s, or legal guardians where applicable,  will 
be given a signed, dated copy of their consent form.  
• The Investigator or his /her representative will explain the natur e of the study to the 
participant or his legally authorized representative and answer all questions regarding 
the study.  
• Participants , and legal guardians where applicable, must be informed that their 
participation is voluntary. Participants or their lega lly authorized representative will 
be required to sign a statement of informed consent that meets the requirements of 
[ADDRESS_1076888] requirements, where applicable, and the IRB/IEC or study center.  
• The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study and the date the written 
consent was obtained. The authorized person obtaining the informed co nsent must 
also sign the ICF.  
• Participants must be re -consented to the most current version of the ICF(s) during 
their participation in the study.  
• A copy of the ICF(s) must be provided to the participant or the participant’s legally 
authorized representat ive.  
The ICF will contain a separate section that addresses the use of remaining mandatory samples 
for . The Investigator or authorized designee will explain to each 
participant the objectives of the . Part icipants , and their legal guardians 
where applicable,  will be told that they are free to refuse to participate and may withdraw their 
consent at any time and for any reason during the storage perio d. 
CCI
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
59 
CONFIDENTIAL  9.1.5.  Data Protection  
[IP_ADDRESS].  Data Safety Monitoring Plan  
All data and  observations will be documented on CRF s by [CONTACT_26300]. A Study 
Monitor will have access to the data to monitor adherence to the protocol and to applicable 
regulations, and the maintenance of adequate and accurate clinical records. A CRF will be 
completed for every patient  that was randomized for participation in the study. The CRF s will be 
completed as data is generated. Additional information can be found in the CRF Completion 
Guidelines .  
9.2. Committees Structure  
9.2.1.  Data Monitoring Committee   
The independent  DMC will act in an advisory capacity to review participant safety and study 
progress for the clinical trial.  For additional information, refer to the Study Operations Manual 
and DMC Charter.   
9.2.2.  Dissemination of Clinical Study Data  
[IP_ADDRESS].  Final Study Re port 
The final study report will include data through the final study visit .  
9.2.3.  Source Documents  
• Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
Investigator’s site.  
• Data reported on the CRF or entered in the e lectronic CRF that are transcribed from 
source documents must be consistent with the source documents or the discrepancies 
must be explained. The Investigator may need to request previous medi cal records or 
transfer records, depending on the study. Also, current medical records must be 
available.  
9.2.4.  Publication Policy  
The information that is developed during the conduct of this clinical study is considered to be 
strictly confidential.  This informa tion may be disclosed only as deemed necessary by [CONTACT_783198], Inc.  At the conclusion of this clinical study, a clinical study report will be 
prepared.  In addition, a manuscript may be prepared for publication in a reputable scientific 
journal under the direction of Sarepta . Sarepta  Therapeutics, Inc.  will publish and communicate 
the clinical study results, irrespective of positive or negative findings.  Data generated for this 
study will be exclusively owned by [CONTACT_515375], Inc., as detailed in the Clinical Trial 
Agreement.  The study will be registered on ClinicalTrials.gov.  After completion of the study, 
results will be disseminated through Clini calTrials.gov.  
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
60 
CONFIDENTIAL  9.3. Appendix 2:   
 
 
CCI
CCI
CCI
SRP-9001  
Protocol  SRP-9001 -102 (Version 9,  Amendment 8)  
[ADDRESS_1076889] igation in Duchenne dystrophy: 2. 
Determination of the “power” of therapeutic trials based on the natural history. Muscle Nerve. 
1983;6(2):91 -103 
D’Amario  D, Amodeo A, Adorisio R, et al. A current approach to heart failure in Duchenne 
muscular dystrophy. Heart. 2017;103(22):1770 -1779.  
Eagle M, Baudouin SV, Chandler C, et al. Survival in Duchenne muscular dystrophy: 
improvements in life expectancy since [ADDRESS_1076890]. 2002;12(10):[ADDRESS_1076891]. 2010;20(11):712 -716. 
Mendell JR, Campbell K, Rodino -Klapac L, et al. Dystrophin immunity in Duchenne’s muscular 
dystrophy. N Engl J Med. 2010;363(15):1429 -1437.  
 
 
CCI
CCI
CCI